Literature DB >> 10796562

Steroids for treating cerebral malaria.

K Prasad1, P Garner.   

Abstract

BACKGROUND: Cerebral malaria is associated with swelling of the brain. Corticosteroid drugs could reduce the harmful effects of this swelling, but could also suppress host immunity to infection.
OBJECTIVES: This review aimed to assess the effects of steroids in patients with cerebral malaria in relation to survival and long-term disability. SEARCH STRATEGY: The Cochrane Controlled Trials Register, the Cochrane Infectious Diseases Group Trials Register, existing reviews, and contact with experts in the field. SELECTION CRITERIA: Randomised controlled trials comparing steroids and no steroids in otherwise identical treatments for patients with cerebral malaria. DATA COLLECTION AND ANALYSIS: Assessments of inclusion criteria, trial quality and data extraction were done by each author independently. The outcomes sought were death, death with life-threatening complications, other complications, and disability. MAIN
RESULTS: Two trials met the inclusion criteria. Out of a total of 143 patients, there were 30 deaths, distributed evenly between the steroid and the comparator group. The researchers reported clinical complications as the number of events in each trial arm, and did not exclude complications occurring in fatalities. This makes it difficult to interpret the reports of significantly more episodes of gastro-intestinal bleeding and seizures in the steroid group. No studies examined disability. REVIEWER'S
CONCLUSIONS: There is currently no evidence of benefit from steroids in this condition, but the small number of participants means it is difficult to exclude an effect on mortality in either direction. Data on clinical complications are difficult to assess.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10796562      PMCID: PMC6532619          DOI: 10.1002/14651858.CD000972

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  13 in total

Review 1.  Malaria: an update on treatment of adults in non-endemic countries.

Authors:  Christopher J M Whitty; David Lalloo; Andrew Ustianowski
Journal:  BMJ       Date:  2006-07-29

Review 2.  Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria.

Authors:  Christy An Okoromah; Bosede B Afolabi; Emma Cb Wall
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

3.  Divergent roles of IRAK4-mediated innate immune responses in two experimental models of severe malaria.

Authors:  Constance A M Finney; Ziyue Lu; Michael Hawkes; Wen-Chen Yeh; W Conrad Liles; Kevin C Kain
Journal:  Am J Trop Med Hyg       Date:  2010-07       Impact factor: 2.345

4.  Cerebral Malaria.

Authors:  Gretchen L. Birbeck
Journal:  Curr Treat Options Neurol       Date:  2004-03       Impact factor: 3.598

5.  Paediatric malaria: What do paediatricians need to know?

Authors:  Susan M Kuhn; Anne E McCarthy
Journal:  Paediatr Child Health       Date:  2006-07       Impact factor: 2.253

6.  A new hypothesis on the manifestation of cerebral malaria: the secret is in the liver.

Authors:  Yuri Chaves Martins; Cláudio Tadeu Daniel-Ribeiro
Journal:  Med Hypotheses       Date:  2013-08-13       Impact factor: 1.538

7.  Glucocorticosteroids in nano-sterically stabilized liposomes are efficacious for elimination of the acute symptoms of experimental cerebral malaria.

Authors:  Judith H Waknine-Grinberg; Simcha Even-Chen; Jasmine Avichzer; Keren Turjeman; Annael Bentura-Marciano; Richard K Haynes; Lola Weiss; Nahum Allon; Haim Ovadia; Jacob Golenser; Yechezkel Barenholz
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

8.  Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.

Authors:  Peter Lackner; Andrea Part; Christoph Burger; Anelia Dietmann; Gregor Broessner; Raimund Helbok; Markus Reindl; Erich Schmutzhard; Ronny Beer
Journal:  Malar J       Date:  2009-02-27       Impact factor: 2.979

9.  Summary of recommendations for the diagnosis and treatment of malaria by the Committee to Advise on Tropical Medicine and Travel (CATMAT).

Authors:  A Boggild; J Brophy; P Charlebois; M Crockett; J Geduld; W Ghesquiere; P McDonald; P Plourde; P Teitelbaum; M Tepper; S Schofield; A McCarthy
Journal:  Can Commun Dis Rep       Date:  2014-04-03

10.  Lipoxin A₄ and 15-epi-lipoxin A₄ protect against experimental cerebral malaria by inhibiting IL-12/IFN-γ in the brain.

Authors:  Nathaniel Shryock; Cortez McBerry; Rosa Maria Salazar Gonzalez; Steven Janes; Fabio T M Costa; Julio Aliberti
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.